ClinicalTrials.gg
CompletedNCT04167514Updated Jul 28, 2026Results posted

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

A Phase 3 interventional study of Alpha-1 antitrypsin (AAT) and Placebo in Graft Versus Host Disease (GVHD), sponsored by CSL Behring. Completed at 25 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
36th of 389
136 · median 30
Started
2020
with 15 others
Phase 3
40 of 454
2 open now
Registered
377th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 36th largest by enrollment of the 389 interventional ones that give a count, is one of 16 that started in 2020, is one of 40 in phase 3, and was the 377th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD

03

Conditions studied

  • Graft Versus Host Disease (GVHD)

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 12 years of age or older
  • Initial presentation of acute after hematopoietic cell transplantation for any indication
  • Any graft or donor source or conditioning intensity
  • Clinical diagnosis of acute GVHD requiring systemic therapy with

Exclusion criteria

Exclusion Criteria:

  • Prior exogenous AAT exposure for prophylaxis
  • , progressing, or persistent
  • de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment
  • Receiving other drugs for the treatment of GVHD
  • Receiving systemic CS for any indication within 7 days before the onset of acute GVHD
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    AAT

    Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration

    Biological: Alpha-1 antitrypsin (AAT)

  • Placebo comparator
    Placebo

    Albumin solution administered intravenously

    Drug: Placebo

Interventions

  • AAT is a lyophilized product for intravenous administration

    Also known as: Alpha-1 proteinase inhibitor (A1-P1)

  • DrugPlacebo

    Albumin solution administered intravenously

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment

    The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 milligrams per kilogram (mg/kg)/day or more. The percentage of participants with CR or PR is reported here. Wilson score confidence intervals (CIs) are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (Mount Sinai Acute GVHD International Consortium \[MAGIC\]) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper gastrointestinal (GI) tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as non-responders (NR).

    Time frame: At Day 28

Secondary outcomes

  1. Duration of Response (DOR)

    The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: progression of acute GVHD, death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to greater than or equal to (\>=) 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.

    Time frame: Up to 12 months

  2. Number of Participants With Non-relapse Mortality (NRM) Event

    An event of NRM was death without prior evidence of relapse/progression of the primary disease, where relapse/progression was treated as a competing risk. Cumulative incidence of NRM at 6 and 12 months post-randomization is reported here for this outcome measure.

    Time frame: At 6 and 12 months

  3. Number of Overall and Progression-free Survival Events

    An event for overall survival (OS) was death from any cause, while an event for progression-free survival (PFS) was death from any cause or relapse/progression of the primary disease.

    Time frame: At 6 and 12 months

  4. Number of Participants With GVHD-free Survival

    GVHD-free survival was defined as participants being alive, free of acute or chronic GVHD, and free of any next-line GVHD therapy or escalation of steroids to \>=2.5 mg/kg/day prednisone or equivalent for treatment of GVHD.

    Time frame: At Day 56

  5. Percentage of Participants With Response

    The percentage of participants with CR, PR (including subset with very good partial response \[VGPR\]), and treatment failure (TF). The designation of TF consisted of participants with NR, mixed response (MR) or progression. The initiation of additional systemic (next-line) GVHD therapies, escalation of prednisone equivalent steroid dose to \>= 2.5 mg/kg/day, or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.

    Time frame: At Day 7, 14, 21, 28, 56, and 86

  6. Percentage of Participants With Response Allowing for Approved Next-line Therapy

    The percentage of participants with CR, PR (including subset with VGPR), and TF allowing for treatment with next-line therapy. The designation of TF consisted of participants with NR, MR, or progression. The escalation of prednisone-equivalent steroid dose to \>= 2.5 mg/kg/day or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.

    Time frame: At Day 7, 14, 21, 28, 56, and 86

  7. Incidence of Grade 2 to 3 Systemic Infections

    The cumulative incidence of Grade 2 to 3 systemic infections. Grade 2 to 3 systemic infections were defined according to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Manual of Procedures.

    Time frame: Up to 90 days (including 30 days after last dose of study drug)

  8. Percentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs)

    The incidence of Grade 3 to 5 TEAEs (per Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0). Wilson score CIs are reported here as a measure of dispersion.

    Time frame: Up to 30 days after the last dose of study drug

  9. Cumulative Incidence of Chronic GVHD

    Chronic GVHD was defined per National Institutes of Health (NIH) Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) was considered an event for this outcome measure, where death before cGVHD was treated as a competing risk.

    Time frame: At 6 and 12 months

  10. Cumulative Incidence of Disease Relapse/ Progression of Primary Disease

    The cumulative incidence of relapse/progression of the primary disease, with death prior to relapse/progression treated as a competing risk. Death without prior relapse/progression was treated as a competing risk for relapse/progression.

    Time frame: At 6 months and 12 months

Other outcomes

  1. DOR - Supplementary Analysis

    The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to \>= 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.

    Time frame: Up to 12 months

07

Results

Posted Aug 29, 2025

Participant flow

This study was conducted at 26 investigative sites in the United States of America.

Participant flow — Overall Study
MilestoneAlpha-1 Antitrypsin (AAT)Placebo
Started6571
Treated6369
Completed3841
Not completed2730
Withdrew: Adverse event, not serious01
Withdrew: Lost to follow-up10
Withdrew: Participant decision24
Withdrew: Physician decision32
Withdrew: Death1418
Withdrew: Enrolled but treatment not administered20
Withdrew: Multiple reasons for study discontinuation documented; including death, primary reason not reported31
Withdrew: Multiple reasons for study discontinuation documented; excluding death, primary reason not reported24

Outcome measures

PrimaryOverall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment

The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 milligrams per kilogram (mg/kg)/day or more. The percentage of participants with CR or PR is reported here. Wilson score confidence intervals (CIs) are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (Mount Sinai Acute GVHD International Consortium \[MAGIC\]) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper gastrointestinal (GI) tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as non-responders (NR).

Time frame:
At Day 28
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment60.0 (47.86 to 71.03)45.1 (34.05 to 56.60)
Statistical analysis
  • Alpha-1 Antitrypsin (AAT) vs Placebo · One-sided Wald · p = 0.034 · Odds ratio (or): 1.92 · 95% CI 0.954 to 3.866Wald CIs
SecondaryDuration of Response (DOR)

The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: progression of acute GVHD, death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to greater than or equal to (\>=) 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.

Time frame:
Up to 12 months
Reported as:
Median · days
Duration of Response (DOR)
daysAlpha-1 Antitrypsin (AAT)Placebo
Duration of Response (DOR)82 (22 to 176)154 (57 to NA)
SecondaryNumber of Participants With Non-relapse Mortality (NRM) Event

An event of NRM was death without prior evidence of relapse/progression of the primary disease, where relapse/progression was treated as a competing risk. Cumulative incidence of NRM at 6 and 12 months post-randomization is reported here for this outcome measure.

Time frame:
At 6 and 12 months
Reported as:
Count of participants · Participants
Number of Participants With Non-relapse Mortality (NRM) Event
ParticipantsAlpha-1 Antitrypsin (AAT)Placebo
At 6 months1214
At 12 months1314
SecondaryNumber of Overall and Progression-free Survival Events

An event for overall survival (OS) was death from any cause, while an event for progression-free survival (PFS) was death from any cause or relapse/progression of the primary disease.

Time frame:
At 6 and 12 months
Reported as:
Number · events
Number of Overall and Progression-free Survival Events
eventsAlpha-1 Antitrypsin (AAT)Placebo
OS: At 6 months1618
OS: At 12 months2023
PFS: At 6 months2528
PFS: At 12 months2729
SecondaryNumber of Participants With GVHD-free Survival

GVHD-free survival was defined as participants being alive, free of acute or chronic GVHD, and free of any next-line GVHD therapy or escalation of steroids to \>=2.5 mg/kg/day prednisone or equivalent for treatment of GVHD.

Time frame:
At Day 56
Reported as:
Count of participants · Participants
Number of Participants With GVHD-free Survival
ParticipantsAlpha-1 Antitrypsin (AAT)Placebo
Number of Participants With GVHD-free Survival2925
SecondaryPercentage of Participants With Response

The percentage of participants with CR, PR (including subset with very good partial response \[VGPR\]), and treatment failure (TF). The designation of TF consisted of participants with NR, mixed response (MR) or progression. The initiation of additional systemic (next-line) GVHD therapies, escalation of prednisone equivalent steroid dose to \>= 2.5 mg/kg/day, or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.

Time frame:
At Day 7, 14, 21, 28, 56, and 86
Reported as:
Number · percentage of participants
Percentage of Participants With Response
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
At Day 7 - CR29.2 (17.86 to 43.97)33.8 (22.03 to 48.00)
At Day 7 - PR33.8 (21.62 to 48.69)25.4 (15.16 to 39.22)
At Day 7 - TF36.9 (24.20 to 51.76)40.8 (28.08 to 54.98)
At Day 14 - CR47.7 (33.66 to 62.10)46.5 (33.11 to 60.38)
At Day 14 - PR23.1 (13.07 to 37.45)14.1 (6.89 to 26.65)
At Day 14 - TF29.2 (17.86 to 43.97)39.4 (26.85 to 53.61)
At Day 21 - CR55.4 (40.79 to 69.10)40.8 (28.08 to 54.98)
At Day 21 - PR9.2 (3.66 to 21.41)9.9 (4.18 to 21.54)
At Day 21 - TF35.4 (22.91 to 50.23)49.3 (35.68 to 63.01)
At Day 28 - CR55.4 (40.79 to 69.10)40.8 (28.08 to 54.98)
At Day 28 - PR4.6 (1.28 to 15.31)4.2 (1.17 to 14.12)
At Day 28 - TF40.0 (26.84 to 54.78)54.9 (40.96 to 68.16)
At Day 56 - CR44.6 (30.90 to 59.21)35.2 (23.22 to 49.42)
At Day 56 - PR6.2 (2.00 to 17.41)4.2 (1.17 to 14.12)
At Day 56 - TF49.2 (35.06 to 63.52)60.6 (46.39 to 73.15)
At Day 86 - CR63.4 (44.82 to 78.72)50.0 (32.30 to 67.70)
At Day 86 - PR2.4 (0.32 to 16.22)10.0 (3.27 to 26.76)
At Day 86 - TF34.1 (19.37 to 52.81)40.0 (23.87 to 58.64)
SecondaryPercentage of Participants With Response Allowing for Approved Next-line Therapy

The percentage of participants with CR, PR (including subset with VGPR), and TF allowing for treatment with next-line therapy. The designation of TF consisted of participants with NR, MR, or progression. The escalation of prednisone-equivalent steroid dose to \>= 2.5 mg/kg/day or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.

Time frame:
At Day 7, 14, 21, 28, 56, and 86
Reported as:
Number · percentage of participants
Percentage of Participants With Response Allowing for Approved Next-line Therapy
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
At Day 7 - CR29.2 (17.86 to 43.97)33.8 (22.03 to 48.00)
At Day 7 - PR36.9 (24.20 to 51.76)31.0 (19.69 to 45.12)
At Day 7 - TF33.8 (21.62 to 48.69)35.2 (23.22 to 49.42)
At Day 14 - CR50.8 (36.48 to 64.94)46.5 (33.11 to 60.38)
At Day 14 - PR29.2 (17.86 to 43.97)26.8 (16.27 to 40.72)
At Day 14 - TF20.0 (10.79 to 34.07)26.8 (16.27 to 40.72)
At Day 21 - CR56.9 (42.26 to 70.47)46.5 (33.11 to 60.38)
At Day 21 - PR15.4 (7.54 to 28.84)18.3 (9.85 to 31.51)
At Day 21 - TF27.7 (16.63 to 42.37)35.2 (23.22 to 49.42)
At Day 28 - CR63.1 (48.24 to 75.80)49.3 (35.68 to 63.01)
At Day 28 - PR9.2 (3.66 to 21.41)14.1 (6.89 to 26.65)
At Day 28 - TF27.7 (16.63 to 42.37)36.6 (24.41 to 50.82)
At Day 56 - CR52.3 (37.90 to 66.34)47.9 (34.39 to 61.70)
At Day 56 - PR13.8 (6.52 to 27.03)4.2 (1.17 to 14.12)
At Day 56 - TF33.8 (21.62 to 48.69)47.9 (34.39 to 61.70)
At Day 86 - CR65.9 (47.19 to 80.63)72.5 (53.62 to 85.74)
At Day 86 - PR7.3 (2.04 to 23.07)10.0 (3.27 to 26.76)
At Day 86 - TF26.8 (13.90 to 45.45)17.5 (7.52 to 35.63)
SecondaryIncidence of Grade 2 to 3 Systemic Infections

The cumulative incidence of Grade 2 to 3 systemic infections. Grade 2 to 3 systemic infections were defined according to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Manual of Procedures.

Time frame:
Up to 90 days (including 30 days after last dose of study drug)
Reported as:
Number · events
Incidence of Grade 2 to 3 Systemic Infections
eventsAlpha-1 Antitrypsin (AAT)Placebo
Incidence of Grade 2 to 3 Systemic Infections2022
SecondaryPercentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs)

The incidence of Grade 3 to 5 TEAEs (per Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0). Wilson score CIs are reported here as a measure of dispersion.

Time frame:
Up to 30 days after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs)
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
Percentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs)46.0 (34.31 to 58.21)65.2 (53.45 to 75.38)
SecondaryCumulative Incidence of Chronic GVHD

Chronic GVHD was defined per National Institutes of Health (NIH) Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) was considered an event for this outcome measure, where death before cGVHD was treated as a competing risk.

Time frame:
At 6 and 12 months
Reported as:
Count of participants · Participants
Cumulative Incidence of Chronic GVHD
ParticipantsAlpha-1 Antitrypsin (AAT)Placebo
At 6 months139
At 12 months2014
SecondaryCumulative Incidence of Disease Relapse/ Progression of Primary Disease

The cumulative incidence of relapse/progression of the primary disease, with death prior to relapse/progression treated as a competing risk. Death without prior relapse/progression was treated as a competing risk for relapse/progression.

Time frame:
At 6 months and 12 months
Reported as:
Count of participants · Participants
Cumulative Incidence of Disease Relapse/ Progression of Primary Disease
ParticipantsAlpha-1 Antitrypsin (AAT)Placebo
At 6 months1414
At 12 months1515
Other pre-specifiedDOR - Supplementary Analysis

The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to \>= 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.

Time frame:
Up to 12 months
Reported as:
Median · days
DOR - Supplementary Analysis
daysAlpha-1 Antitrypsin (AAT)Placebo
DOR - Supplementary AnalysisNA (85 to NA)NA (109 to NA)
Post-hocORR to Acute GVHD Treatment: Gender Subgroup

The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or more. The percentage of participants with CR or PR based on gender subgroup is reported here. Clopper-Pearson CIs are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (MAGIC) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper GI tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as NR.

Time frame:
At Day 28
Reported as:
Number · percentage of participants
ORR to Acute GVHD Treatment: Gender Subgroup
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
Male57.8 (42.15 to 72.34)46.2 (30.09 to 62.82)
Female65.0 (40.78 to 84.61)43.8 (26.36 to 62.34)
Post-hocORR to Acute GVHD Treatment: Race Subgroup

The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or more. Percentage of participants with CR or PR based on race subgroup is reported here. Clopper-Pearson CIs are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (MAGIC) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper GI tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as NR. The "Non-White" subgroup includes: American Indian/Alaska Native, Asian, Black or African American, Hawaiian/Pacific Islander, More than One Race, and Unknown.

Time frame:
At Day 28
Reported as:
Number · percentage of participants
ORR to Acute GVHD Treatment: Race Subgroup
percentage of participantsAlpha-1 Antitrypsin (AAT)Placebo
White58.8 (44.17 to 72.42)39.3 (27.07 to 52.69)
Non-white64.3 (35.14 to 87.24)80.0 (44.39 to 97.48)

Adverse events

Collected over From randomization to 12 months (end of study [EOS] follow-up): AEs and Serious AEs (SAEs) reported from randomization until 30 days post last dose. Beginning at 31 days from the last dose of the study drug through the EOS follow-up, only SAEs related to the study drug and unanticipated SAEs (regardless of relationship) required reporting. All-cause mortality includes any deaths, regardless of the timing, including those reported beyond the 12 months, up to 16 months for the last reported death.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1 Antitrypsin (AAT)21/65 (32.3%)11/63 (17.5%)37/63 (58.7%)
Placebo23/71 (32.4%)23/69 (33.3%)42/69 (60.9%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventAlpha-1 Antitrypsin (AAT)Placebo
FallInjury, poisoning and procedural complications0/634/69
Oedema peripheralGeneral disorders2/630/69
Small intestinal obstructionGastrointestinal disorders0/632/69
Acute kidney injuryRenal and urinary disorders0/632/69
Subdural haematomaInjury, poisoning and procedural complications1/630/69
Intracranial massNervous system disorders1/630/69
SyncopeNervous system disorders1/630/69
Toxic encephalopathyNervous system disorders1/630/69
DysphagiaGastrointestinal disorders1/630/69
HypokalaemiaMetabolism and nutrition disorders1/630/69
Most frequent other events
Showing 10 of 37
Most frequent other events
EventAlpha-1 Antitrypsin (AAT)Placebo
HyperglycaemiaMetabolism and nutrition disorders13/6311/69
Oedema peripheralGeneral disorders12/6310/69
HypocalcaemiaMetabolism and nutrition disorders7/6312/69
Alanine aminotransferase increasedInvestigations7/6311/69
HypomagnesaemiaMetabolism and nutrition disorders10/6310/69
HypertensionVascular disorders9/6310/69
HypoalbuminaemiaMetabolism and nutrition disorders9/636/69
Abdominal painGastrointestinal disorders9/636/69
HyperkalaemiaMetabolism and nutrition disorders6/639/69
HyponatraemiaMetabolism and nutrition disorders6/639/69

Baseline characteristics

Analysis was performed on the intent-to-treat (ITT) population. The ITT population consisted of all randomized participants, classified according to their randomized treatment assignments. All randomized participants were included, regardless of whether the assigned study treatment was truly administered.

Age, Continuous
Age, Continuous(years)Alpha-1 Antitrypsin (AAT)PlaceboTotal
Mean56.6 ± 12.6555.3 ± 13.7555.9 ± 13.20
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1 Antitrypsin (AAT)PlaceboTotal
Female203252
Male453984
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alpha-1 Antitrypsin (AAT)PlaceboTotal
Hispanic or Latino8311
Not Hispanic or Latino5666122
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpha-1 Antitrypsin (AAT)PlaceboTotal
American Indian or Alaska Native000
Asian527
Native Hawaiian or Other Pacific Islander000
Black or African American369
White5161112
More than one race000
Unknown or Not Reported628
08

Study locations

25 sites
  • Stanford University
    Stanford, California 94305, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322-1059, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • IU Hospital
    Indianapolis, Indiana 46202, United States
  • Univ. of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • U-M Medical Center
    Ann Arbor, Michigan 48109-0312, United States
  • Karmanos Cancer Center
    Detroit, Michigan 48201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • MSKCC
    New York, New York 10065, United States
  • Levine Cancer Center
    Charlotte, North Carolina 28204, United States
  • Duke
    Durham, North Carolina 27705, United States
  • Cleveland Clinic
    Cleveland, Ohio 44124, United States
  • Ohio State Univ.Medical Center
    Columbus, Ohio 43210, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Center for Gene Therapy
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Commonwealth Univ.
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Clinic
    Seattle, Washington 98109, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Sep 2023, 44 months.

Results were first posted in Aug 2025, 1 year 11 months after primary completion.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Nov 19, 2019
StartActual
Jan 9, 2020
Primary completionActual
Sep 11, 2023
CompletionActual
Jun 26, 2024
Results first posted
Aug 29, 2025
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04167514
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Jan 9, 2020
Primary completion
Sep 11, 2023
Completion
Jun 26, 2024
Results posted
Aug 29, 2025
Last update
Jul 28, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion